What Does the Science Say About Tysabri and PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Occupational Hazard Assessment

If you or someone you know is taking Tysabri, concerns about progressive multifocal leukoencephalopathy (PML) may feel overwhelming. The medical community has long relied on systematic research to understand how therapies interact with the body, and this tradition of careful investigation informs our current knowledge of Tysabri's risks. This page reviews the evidence on Tysabri and PML, covering risk factors, monitoring strategies, and what patients and providers should discuss.

Tysabri and PML: A Documented Causal Association

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, to communicate this risk. The boxed warning explicitly states that Tysabri increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, with dosing withheld immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning further notes that risk factors for developing PML include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy.

Mechanistic Pathway and Clinical Evidence

The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of immune cells across the blood-brain barrier. This reduces central nervous system immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic clinical presentation of PML. Clinical presentation typically includes progressive neurological deficits such as hemiparesis, visual disturbances, cognitive decline, and ataxia. Diagnosis is confirmed by brain MRI showing multifocal white matter lesions and detection of JCV DNA in cerebrospinal fluid. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 multiple sclerosis patients treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1,043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data underscore that PML can develop within the first year of treatment, though risk increases with longer exposure.

Regulatory Warnings and Causation Considerations

Regarding the adequacy of warnings, the FDA has mandated a boxed warning and a restricted distribution program called the TOUCH Prescribing Program, which requires prescribers, patients, and pharmacies to enroll and comply with specific monitoring and education requirements (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label instructs physicians to consider risk factors when initiating and continuing treatment and to monitor patients for new neurological symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, despite these measures, PML remains a known adverse reaction, and the label acknowledges that it usually leads to death or severe disability. Causation considerations for affected patients involve establishing a temporal relationship between Tysabri exposure and PML onset. The timeline can vary: PML has been reported after as few as eight doses (approximately 4 weeks) and after longer treatment durations beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The presence of anti-JCV antibodies is a key risk factor, and prior immunosuppressant use further elevates risk. For patients who develop PML, the drug's role is considered causal given the biological plausibility and clinical trial evidence. The label explicitly states that Tysabri increases the risk of PML, and the boxed warning emphasizes that the infection usually leads to death or severe disability. In summary, the evidence demonstrates a clear causal link between Tysabri and PML, supported by pharmacological mechanism, clinical trial data, and regulatory warnings.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the causal link between Tysabri and PML?

Tysabri (natalizumab) increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. The FDA has issued a boxed warning stating that Tysabri increases the risk of PML, which usually leads to death or severe disability. The causal link is supported by pharmacological mechanism, clinical trial data, and regulatory warnings (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be weighed against expected benefits when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in patients exposed to Tysabri?

Diagnosis is confirmed by brain MRI showing multifocal white matter lesions and detection of JCV DNA in cerebrospinal fluid. Clinical presentation typically includes progressive neurological deficits such as hemiparesis, visual disturbances, cognitive decline, and ataxia.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.